Hyperphagia severity is underestimated in adults with Bardet-Biedl syndrome – a mixed-method cross-sectional study in the United Kingdom - Scorecard - MDSpire
Advertisement
Hyperphagia severity is underestimated in adults with Bardet-Biedl syndrome – a mixed-method cross-sectional study in the United Kingdom
Clinical Scorecard: Underestimation of Hyperphagia Severity in Adults with Bardet-Biedl Syndrome: A Cross-Sectional Mixed-Methods Study Conducted in the UK
At a Glance
Category
Detail
Condition
Bardet-Biedl Syndrome
Key Mechanisms
Primary ciliary dysfunction leading to hyperphagia and early-onset obesity due to disruption of the melanocortin-4 receptor pathway.
Target Population
Adults with Bardet-Biedl Syndrome in the UK.
Care Setting
Clinical assessment of hyperphagia severity.
Key Highlights
Hyperphagia severity was classified as severe in 66.7% of participants based on semi-structured interviews.
Self-reported questionnaires underestimated hyperphagia severity compared to interviews.
86.7% of participants had higher severity ratings in interviews than in questionnaires.
The study included 51 adults with BBS, predominantly of White ethnicity.
Hyperphagia is linked to significant impacts on quality of life and health outcomes.
Guideline-Based Recommendations
Diagnosis
Utilize both structured questionnaires and semi-structured interviews to assess hyperphagia.
Management
Consider the use of treatments like setmelanotide for managing hyperphagia.
Monitoring & Follow-up
Regularly evaluate hyperphagia severity using comprehensive assessment tools.
Risks
Underestimation of hyperphagia severity can lead to inadequate management and worsening health outcomes.
Patient & Prescribing Data
Adults diagnosed with Bardet-Biedl Syndrome.
Current treatments for hyperphagia may be underused due to underreporting of severity.
Clinical Best Practices
Incorporate mixed-methods approaches for assessing hyperphagia in clinical settings.
Educate patients and caregivers about the impacts of hyperphagia on health and quality of life.